» Articles » PMID: 24637880

Old Habits Die Hard: a Nationwide Utilization Study of Short-acting Nifedipine in Taiwan

Overview
Journal PLoS One
Date 2014 Mar 19
PMID 24637880
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the nationwide trend of ambulatory prescriptions of short-acting nifedipine on a PRN (pro re nata) order over a fifteen-year period in Taiwan.

Methods: The systematic sampling claims datasets (0.2% sampling ratio) of ambulatory care visits within Taiwan's National Health Insurance from 1997 to 2011 were analyzed. The prescriptions of short-acting capsule-form nifedipine on a PRN order were stratified by the patient's age, the prescribing physician's specialty, and the setting of healthcare facility for each year.

Results: During the study period, 8,189,681 visits were analyzed. While the utilization rate of calcium channel blockers changed with time from 2.8% (13,767/489,636) in 1997 to 5.1% (31,349/614,719) in 2011, that of short-acting nifedipine were from 1.0% (n = 5,070) to 0.2% (n = 1,246). However, short-acting capsule-form nifedipine on a PRN order still existed (from 447 prescriptions in 1997 to 784 in 2011). More than one half of these PRN nifedipines were prescribed by the internists and to the elderly patients; almost four-fifths of PRN nifedipines were prescribed during non-emergent consultations.

Conclusion: The physicians in Taiwan still had the habit of prescribing short-acting nifedipines for PRN use. The reason for such practices and the impact on patients' health deserve attention.

Citing Articles

Oral short-acting antihypertensive medications and the occurrence of stroke: a nationwide case-crossover study.

Hsu C, Huang L, Saver J, Wu Y, Lee J, Chen P Hypertens Res. 2019; 42(11):1794-1800.

PMID: 31300722 DOI: 10.1038/s41440-019-0300-0.


Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study.

Wang Z, White D, Hoogeveen R, Chen L, Whitsel E, Richardson P J Clin Med. 2018; 7(8).

PMID: 30072610 PMC: 6111748. DOI: 10.3390/jcm7080197.

References
1.
Jung S, Choi N, Kim J, Chang Y, Song H, Lee J . Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology. 2011; 77(13):1229-34. DOI: 10.1212/WNL.0b013e318230201a. View

2.
Gu Q, Paulose-Ram R, Dillon C, Burt V . Antihypertensive medication use among US adults with hypertension. Circulation. 2006; 113(2):213-21. DOI: 10.1161/CIRCULATIONAHA.105.542290. View

3.
Marwick C . FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 1996; 275(6):423-4. View

4.
Grossman E, Messerli F . Calcium antagonists. Prog Cardiovasc Dis. 2004; 47(1):34-57. DOI: 10.1016/j.pcad.2004.04.006. View

5.
Egger D, Deming D, Hamada N, Perkin R, Sahney S . Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol. 2002; 17(1):35-40. DOI: 10.1007/s004670200006. View